JP2002517249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002517249A5 JP2002517249A5 JP2000553593A JP2000553593A JP2002517249A5 JP 2002517249 A5 JP2002517249 A5 JP 2002517249A5 JP 2000553593 A JP2000553593 A JP 2000553593A JP 2000553593 A JP2000553593 A JP 2000553593A JP 2002517249 A5 JP2002517249 A5 JP 2002517249A5
- Authority
- JP
- Japan
- Prior art keywords
- ebv
- use according
- epitope
- sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 5
- 102000011412 Complement 3d Receptors Human genes 0.000 description 4
- 108010023729 Complement 3d Receptors Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 tetrafluoroborate Chemical compound 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8915898P | 1998-06-12 | 1998-06-12 | |
| US60/089,158 | 1998-06-12 | ||
| PCT/US1999/013113 WO1999064603A2 (en) | 1998-06-12 | 1999-06-10 | ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116568A Division JP2012214477A (ja) | 1998-06-12 | 2012-05-22 | 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002517249A JP2002517249A (ja) | 2002-06-18 |
| JP2002517249A5 true JP2002517249A5 (enExample) | 2006-07-13 |
| JP5138844B2 JP5138844B2 (ja) | 2013-02-06 |
Family
ID=22216014
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553593A Expired - Fee Related JP5138844B2 (ja) | 1998-06-12 | 1999-06-10 | 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強 |
| JP2012116568A Pending JP2012214477A (ja) | 1998-06-12 | 2012-05-22 | 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116568A Pending JP2012214477A (ja) | 1998-06-12 | 2012-05-22 | 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6432679B1 (enExample) |
| EP (1) | EP1086231A2 (enExample) |
| JP (2) | JP5138844B2 (enExample) |
| AU (1) | AU762799B2 (enExample) |
| CA (1) | CA2331258C (enExample) |
| WO (1) | WO1999064603A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248334B1 (en) * | 1997-01-08 | 2001-06-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process |
| JP5138844B2 (ja) * | 1998-06-12 | 2013-02-06 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強 |
| FR2819724B1 (fr) * | 2001-01-22 | 2005-05-13 | Inst Necker | Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus |
| US6820011B2 (en) * | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
| GB0210682D0 (en) * | 2002-05-09 | 2002-06-19 | Glaxosmithkline Biolog Sa | Novel use |
| CA2499075A1 (en) * | 2002-09-16 | 2004-03-25 | Elusys Therapeutics, Inc. | Production of bispecific molecules using polyethylene glycol linkers |
| EP2292259A3 (en) * | 2002-11-15 | 2011-03-23 | MUSC Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| CN1787835A (zh) * | 2003-02-21 | 2006-06-14 | 哈苏米有限责任公司 | 人淋巴细胞疫苗佐剂 |
| WO2005072778A2 (en) * | 2004-01-29 | 2005-08-11 | Biosynexus, Inc. | Use of amino-oxy functional groups in the preparation of vaccines conjugates |
| AU2006329215A1 (en) * | 2005-12-22 | 2007-06-28 | Conjuchem Biotechnologies Inc. | Process for the production of preformed conjugates of albumin and a therapeutic agent |
| AU2007261315B2 (en) | 2006-06-21 | 2012-10-25 | Musc Foundation For Research Development | Targeting complement factor H for treatment of diseases |
| AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| CN102470167A (zh) | 2009-07-02 | 2012-05-23 | Ith免疫治疗控股公司 | 基于外泌体的癌症治疗 |
| US8647621B2 (en) | 2009-07-27 | 2014-02-11 | Fina Biosolutions, Llc | Method of producing protein-carbohydrate vaccines reduced in free carbohydrate |
| EA201290286A1 (ru) | 2009-11-05 | 2013-01-30 | Алексион Кембридж Корпорейшн | Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза |
| KR101635795B1 (ko) | 2009-12-17 | 2016-07-04 | 피나 바이오솔루션스, 엘엘씨 | 다당류/단백질 접합체 백신의 제조에 있어서 시안화제인 1-시아노벤조트리아졸 (1-cbt)을 통한 다당류의 활성화 |
| EP2560738B8 (en) | 2010-04-23 | 2019-09-25 | Serum Institute of India Private Limited | Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels |
| SG185483A1 (en) | 2010-05-14 | 2012-12-28 | Univ Colorado Regents | Improved complement receptor 2 (cr2) targeting groups |
| EP2585110A4 (en) | 2010-06-22 | 2014-01-22 | Univ Colorado Regents | ANTIBODIES AGAINST THE C3D FRAGMENT OF THE COMPLEMENT COMPONENT 3 |
| AU2013295647B2 (en) * | 2012-07-26 | 2018-02-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| EP0436626A1 (en) | 1988-10-03 | 1991-07-17 | Scripps Clinic And Research Foundation | THE RECEPTOR BINDING REGION OF EBVgp350 |
| US5280113A (en) | 1989-08-16 | 1994-01-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
| US5331090A (en) | 1989-09-08 | 1994-07-19 | California Institute Of Biological Research | CR2 ligand compositions and methods for modulating immune cell functions |
| US5310729A (en) | 1990-04-20 | 1994-05-10 | California Institute Of Biological Research | Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions |
| KR950700081A (ko) | 1992-02-11 | 1995-01-16 | W 로우 죤 | 이중 캐리어 면역원성 구성물 |
| WO1993019092A1 (fr) | 1992-03-19 | 1993-09-30 | Centre National De La Recherche Scientifique | Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr |
| US5521066A (en) | 1993-09-13 | 1996-05-28 | Bristol-Myers Squibb Company | Periplasmic membrane-bound system for detecting protein-protein interactions |
| ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
| MY114769A (en) * | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
| GB9424631D0 (en) * | 1994-12-06 | 1995-01-25 | Lynxvale Ltd | Modulating the immune response |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| EP0814833B1 (en) * | 1995-03-22 | 2003-05-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
| JP5138844B2 (ja) * | 1998-06-12 | 2013-02-06 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強 |
-
1999
- 1999-06-10 JP JP2000553593A patent/JP5138844B2/ja not_active Expired - Fee Related
- 1999-06-10 AU AU45594/99A patent/AU762799B2/en not_active Ceased
- 1999-06-10 EP EP19990928550 patent/EP1086231A2/en not_active Withdrawn
- 1999-06-10 US US09/328,599 patent/US6432679B1/en not_active Expired - Lifetime
- 1999-06-10 WO PCT/US1999/013113 patent/WO1999064603A2/en not_active Ceased
- 1999-06-10 CA CA 2331258 patent/CA2331258C/en not_active Expired - Fee Related
-
2012
- 2012-05-22 JP JP2012116568A patent/JP2012214477A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002517249A5 (enExample) | ||
| Virelizier et al. | Antibody responses to antigenic determinants of influenza virus hemagglutinin: I. Thymus dependence of antibody formation and thymus independence of immunological memory | |
| JP2768928B2 (ja) | ウシ乳頭腫ウィルスのｄｎａ断片 | |
| CN112521511B (zh) | 一种含EB病毒gB蛋白的自组装纳米颗粒及其制备方法与应用 | |
| JP2858848B2 (ja) | Ｂ型肝炎ウイルスコア抗原粒子 | |
| JP2528815B2 (ja) | 多効果免疫性蛋白質 | |
| CA2331846A1 (en) | Expression vectors for stimulating an immune response and methods of using the same | |
| JP2002532387A (ja) | ペプチドリガンドを介して結合された複数の免疫原性成分を有するｈｂｖコア抗原粒子 | |
| JP2002520000A5 (enExample) | ||
| JPH063445B2 (ja) | 抗原活性アミノ酸連鎖の決定方法 | |
| WO1984003506A1 (en) | Antigenically active amino acid sequences | |
| JPS63218627A (ja) | ロタウイルスヌクレオキャプシドタンパクｖｐ６のワクチン組成物への使用 | |
| Perham et al. | Engineering a peptide epitope display system on filamentous bacteriophage | |
| WO1992020805A1 (en) | Recombinant dna coding for signal peptide, selective interacting polypeptide and membrane anchoring sequence | |
| US8685694B2 (en) | Methods and compositions comprising bacteriophage nanoparticles | |
| CA2816401C (en) | Generation of antigenic virus-like particles through protein-protein linkages | |
| Redmond et al. | Rotavirus particles function as immunological carriers for the delivery of peptides from infectious agents and endogenous proteins | |
| JP2002515249A5 (enExample) | ||
| CN118286410B (zh) | 一种偶联CD8抗体的肿瘤mRNA疫苗的制备方法 | |
| CN117797252B (zh) | 一种基于dna纳米技术的病毒多肽-蛋白亚单位组合疫苗及其制备方法和应用 | |
| Sjolander et al. | Bacterial Expression Systems Based on a Protein A and Protein G Designed for the Production of Immunogens: Applications to Plasmodium falciparum Malaria Antigens | |
| Shon et al. | Antibodies raised against peptide fragments of bovine αs1‐casein cross‐react with the native protein, but recognize sites distinct from the determinants on the protein | |
| CN118576725A (zh) | 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用 | |
| Gao et al. | A dominant Th epitope in influenza nucleoprotein. Analysis of the fine specificity and functional repertoire of T cells recognizing a single determinant. | |
| Knowles et al. | Linear B-cell epitopes in the N-terminus of L2 of bovine papillomavirus type 4 |